Sagimet Biosciences appoints Thierry Chauche as CFO, effective May 6, 2024

Sagimet Biosciences Inc.

Thierry Chauche named CFO, replacing interim CFO Joseph Oriti who resigned.
Chauche receives $480k base salary, 40% target bonus, and option grant valued at $2M (Black-Scholes).
Option vests over 4 years (25% cliff at 1 year, then monthly).
Severance: 6 months base salary (12 months during change in control), plus COBRA and equity acceleration.
Chauche previously CFO of Provention Bio and held roles at Alexion, Intercept, Novartis.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Thierry Chauche

Chief Financial Officer

SGMT · Sagimet Biosciences Inc.

Effective: 2024-05-06
Filed: May 6, 2024, 7:59 PM ET

On May 3, 2024, the Board of Directors (the “Board”) of Sagimet Biosciences Inc. (the “Company”) appointed Thierry Chauche as the Company’s Chief Financial Officer, effective May 6, 2024.

Departed (interim)

Joseph Oriti

interim Principal Financial Officer and interim Principal Accounting Officer

SGMT · Sagimet Biosciences Inc.

Effective: 2024-05-05
Successor: Thierry Chauche
Filed: May 6, 2024, 7:59 PM ET

On May 5, 2024, Joseph Oriti, the Company’s interim Principal Financial Officer and interim Principal Accounting Officer resigned in connection with Mr. Chauche’s appointment.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Thierry Chauche was appointed as Chief Financial Officer at Sagimet Biosciences Inc..

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

On May 3, 2024, the Board of Directors (the “Board”) of Sagimet Biosciences Inc. (the “Company”) appointed Thierry Chauche as the Company’s Chief Financial Officer, effective May 6, 2024.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

Joseph Oriti resigned as interim Principal Financial Officer and interim Principal Accounting Officer at Sagimet Biosciences Inc..

Action: resigned
Role: interim Principal Financial Officer and interim Principal Accounting Officer

Exact text from the filing

On May 5, 2024, Joseph Oriti, the Company’s interim Principal Financial Officer and interim Principal Accounting Officer resigned in connection with Mr. Chauche’s appointment.

View on SEC.gov

Sagimet Biosciences Inc. filing history →

Source: SEC EDGAR

accession 0001104659-24-057228

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.